Merck (MRK) Looks to Acquire Seagen (SGEN) - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Morgan Stanley Calls Seagen (SGEN) A Catalyst Driven Idea for 'Pivotal Padcev Data in 1L Bladder Cancer'
June 21, 2022 4:22 PM EDTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $173.00 price target on Seagen (NASDAQ: SGEN).
The analyst comments "Padcev (Enfortumab vedotin or EV) is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4 (a cell surface protein expressed on many... More
Seagen (SGEN) Seen Worth $200+ in a Takeover
June 21, 2022 12:53 PM EDTSeagen (NASDAQ: SGEN) is adding to Friday's gains as traders handicap the sale of the company following reports on Friday from the WSJ that Merck (NYSE: MRK) and others are eyeing a takeover of the biotech company.
Several analysts have weighed in on the potential deal and many view $200+ as the benchmark needed to get the deal done.
Oppenheimer analyst Jay Olson raised his price target on Seagen to $208 per share following the Merck speculation, which he thinks makes sense given recent dynamics, including:
1) SGEN and MRK... More
